ArticlePharmaceuticals (Basel, Switzerland)2023
Span 60/Cholesterol Niosomal Formulation as a Suitable Vehicle for Gallic Acid Delivery with Potent In Vitro Antibacterial, Antimelanoma, and Anti-Tyrosinase Activity.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Niosomal Encapsulation of Phenolic-Rich Extract from Fermented Corn Bran: Optimization, Characterization, and In Vitro Evaluation.Foods (Basel, Switzerland) · 2026Article
- Formulation, characterization and evaluation of cytotoxic potential for febuxostat loaded chitosomes against cervical cancer cells (Hela cells).Scientific reports · 2026Article
- Preparation and Characterization of Niosomes Containing Cationic Antimicrobial Peptides WSKK11 and WSRR11.ACS omega · 2026Article
- Puerarin-Loaded Proniosomal Gel: Formulation, Characterization,Gels (Basel, Switzerland) · 2026Article
- Vanillic Acid-Loaded Niosomes for Diabetic Wound Healing: Formulation, Optimization by Box-Behnken Design, and In Vivo Evaluation.AAPS PharmSciTech · 2026Article
- Coarse-grained molecular dynamics simulation of gallic acid delivery using span60-based niosomes.Scientific reports · 2026Article
- Surfactant-Engineered Niosomal Antibiotic Systems for Biofilm-Associated Infections: Design Principles and Translational Perspectives.International journal of nanomedicine · 2026Review
- Formulation and Characterization of Oxiconazole-Loaded Novasomes to Enhance the Treatment of Fungus Infections: Experimentally Induced Candidiasis in Rat.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Enhanced behavioral impact of optimized bupropion-encapsulated bilosomes over traditional niosomes treating depression.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Stearyl amine tailored spanlastics embedded within tetronicDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics.Gels (Basel, Switzerland) · 2025Article
- Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration.International journal of nanomedicine · 2025Article
- Recent Advancements in Gallic Acid-Based Drug Delivery: Applications, Clinical Trials, and Future Directions.Pharmaceutics · 2024Review
- Ultrasonic synthesis of green lipid nanocarriers loaded with Scutellaria barbata extract: a sustainable approach for enhanced anticancer and antibacterial therapy.Bioprocess and biosystems engineering · 2024Article
- Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Enhanced bioavailability of Quercetin-loaded niosomal in situ gel for the management of Parkinson's disease.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural compounds such as gallic acid (GA) have attracted more attention in cosmetic and pharmaceutical skin care products. However, the low solubility and poor stability of GA have limited its application. This study aimed to synthesize and characterize the GA niosomal dispersion (GAN) and investigate the potential of an optimal formulation as a skin drug delivery system for GA. For this purpose, GAN formulations were synthesized using the thin layer evaporation method with different molar ratios of Tween 60/Span 60, along with a constant molar ratio of polyethylene glycol 4000 (PEG-4000) and cholesterol in a methanol and chloroform solvent (1:4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.